CFA
ANIK icon

Carroll Financial Associates’s Anika Therapeutics ANIK Stock Holding History

Carroll Financial Associates’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-96
Closed -$2K – 1504
2020
Q1 		$2K Hold
96
– – ﹤0.01% 1274
2019
Q4 		$4K Hold
96
– – ﹤0.01% 1266
2019
Q3 		$5K Hold
96
– – ﹤0.01% 1170
2019
Q2 		$3K Buy
+96
New +$3.5K ﹤0.01% 1293

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Carroll Financial Associates's ANIK Position: Q2 2020 in Review

Carroll Financial Associates sold out of Anika Therapeutics (ANIK) in Q2 2020, closing a stake of 96 shares — an estimated $2K sold.

Carroll Financial Associates first reported a position in ANIK in Q2 2019 and held it in 4 quarters. The position peaked at $5K in Q3 2019. 158 funds tracked by Wall St. Rank hold ANIK as of Q2 2020.

  • Carroll Financial Associates reported no remaining Anika Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Carroll Financial Associates sold 96 Anika Therapeutics shares in Q2 2020, an estimated $2K.
  • Carroll Financial Associates first reported a position in Anika Therapeutics in Q2 2019 and held it in 4 quarters.
  • Carroll Financial Associates's Anika Therapeutics position peaked at $5K in Q3 2019.
  • 158 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2020.

Based on Carroll Financial Associates's 13F filing for Q2 2020, filed 9 Jul 2020.